Core Insights - Entera Bio Ltd. is advancing EB613, an oral anabolic PTH(1-34) tablet treatment aimed at high-risk post-menopausal women with osteoporosis, with abstracts accepted for presentation at the WCO-IOF-ESCEO congress in April 2025 [1][2][4] Company Overview - Entera Bio is a clinical-stage company focused on developing oral peptide and protein replacement therapies, leveraging its proprietary N-Tab™ technology platform [7] - The company's pipeline includes five first-in-class oral peptide programs targeting PTH(1-34), GLP-1, and GLP-2, with EB613 being the most advanced candidate [7] Product Development - EB613 is designed to provide an anabolic boost to strengthen skeletal microarchitecture and induce rapid bone mineral density (BMD) gains, followed by consolidation with an antiresorptive agent [6] - A placebo-controlled Phase 2 study of EB613 demonstrated significant increases in BMD at all skeletal sites and improvements in bone formation and resorption markers [2][6] Market Need - Osteoporosis is a significant health concern, affecting approximately 200 million women globally, with a high risk of fragility fractures among individuals over 50 [5] - Current injectable anabolic treatments are not viable for most patients, highlighting the need for a simple oral treatment like EB613 [6] Upcoming Presentations - Two abstracts related to EB613 will be presented at the WCO-IOF-ESCEO congress, including an oral presentation on the effects of EB613 on trabecular and cortical bone and a poster presentation on pharmacokinetics [3]
EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases